Agilent Technologies Inc vs Global X Uranium ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.22B), while Global X Uranium ETF trades at $45.09. The key difference: Agilent Technologies Inc pays a 0.68% dividend while Global X Uranium ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| A | URA | |
|---|---|---|
Market Cap | $42.22B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $157.20 | $61.81 |
52-Week Low | $110.24 | $36.45 |
Enterprise Value | $43.77B | — |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.23, near its consensus price target of $154.90, with a slight 0.33% decline over 24 hours. The stock shows strong fundamentals, including a 19.55% net income margin and robust ROE of 21.33%, while technical indicators signal a bullish trend despite overbought RSI levels. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, reinforcing growth in biopharma services.
Outlook remains positive with 77.5% analyst buy ratings, but risks include high valuation multiples (P/E 30.02) and dependence on healthcare spending. Earnings beat in Q1 2026 supports upside, though Q2 2026 results due August 26 are critical for momentum. Institutional accumulation, like Ashton Thomas Securities' 47.1% stake increase in Q2 2026, underscores confidence.
URA, the Global X Uranium ETF, trades at $45.34, up 2.16% today with a bullish technical signal from moving averages. The ETF benefits from strong nuclear energy tailwinds including $17.5 billion in federal funding and growing AI power demand. Recent index additions like Terra Innovatum and Eagle Nuclear Energy expand the fund's exposure to nuclear infrastructure companies.
The uranium sector faces near-term volatility but long-term structural growth drivers remain intact. Key risks include policy uncertainty and uranium price fluctuations, while opportunities stem from nuclear energy's role in meeting AI power demands and global decarbonization goals.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →